EcoDrugPlus

Purinergic Receptor P2x 3

Ensembl ID : ENSCDRG00005002123
Gene Symbol: P2RX3
3 Cross references
272 Possible Orthologues:

Purinergic Receptor P2x 7

Ensembl ID : ENSCDRG00005015733
Gene Symbol: P2RX7
1 Cross references
195 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSCDRG00005000045
Gene Symbol: P2RY1
1 Cross references
191 Possible Orthologues:

Purinergic Receptor P2y12

Ensembl ID : ENSCDRG00005016800
Gene Symbol: P2RY12
1 Cross references
182 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSCDRG00005001935
Gene Symbol: P2RY2
3 Cross references
200 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSCDRG00005001948
Gene Symbol: P2RY6
3 Cross references
183 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSCDRG00005015618
Gene Symbol: RAMP1
1 Cross references
252 Possible Orthologues:

Receptor Interacting Serine/threonine Kinase 1

Ensembl ID : ENSCDRG00005015351
Gene Symbol: RIPK1
1 Cross references
198 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSCDRG00005013274
Gene Symbol: RPTOR
1 Cross references
208 Possible Orthologues:

Renin

Ensembl ID : ENSCDRG00005016286
Gene Symbol: REN
3 Cross references
220 Possible Orthologues:

Ret Proto-Oncogene

Ensembl ID : ENSCDRG00005007057
Gene Symbol: RET
1 Cross references
205 Possible Orthologues:

Retinoic Acid Receptor Alpha

Ensembl ID : ENSCDRG00005007055
Gene Symbol: RARA
3 Cross references
331 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).